Publication Date



Nature Medicine


Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg


Adult, Antiretroviral Therapy, Highly Active, Antiviral Agents, Broadly Neutralizing Antibodies, CD4-Positive T-Lymphocytes, Double-Blind Method, Female, HIV Envelope Protein gp120, HIV Infections, HIV-1, Humans, Male, Middle Aged, Peptide Fragments, Placebos, Viral Load, Young Adult



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.